南昌大学学报（医学版）
南昌大學學報（醫學版）
남창대학학보（의학판）
ACTA ACADEMIAE MEDICINAE JIANGXI
2014年
9期
38-41
,共4页
玉海%梁建波%胡斌%蓝志相
玉海%樑建波%鬍斌%藍誌相
옥해%량건파%호빈%람지상
膀胱癌%Fas/FasL 系统%血清%可溶性%应用价值
膀胱癌%Fas/FasL 繫統%血清%可溶性%應用價值
방광암%Fas/FasL 계통%혈청%가용성%응용개치
bladder carcinoma%Fas/FasL system%serum,solubile%application value
目的：探讨血清可溶性 Fas（sFas）及 FasL（sFasL）含量变化与膀胱癌病理特征的关系，以确定血清 sFas 及sFasL 含量检测在临床上的应用价值。方法采用酶联免疫吸附试验（Elisa）定量检测78例膀胱癌患者（膀胱癌组，浅表性膀胱癌54例，浸润性膀胱癌24例；G1期20例，G2期39例，G3期19例）术前、术后和30例健康体检者（对照组）血清中 sFas 和 sFasL 的水平。观察血清 sFas 和 sFasL 含量的变化与膀胱癌病理特征的关系。结果膀胱癌组术前血清中 sFas 和 sFasL 含量分别为（18．53±1．74）、（13．46±1．57）μg·L－1，明显高于术后及对照组[（7．03±1．54）、（4．38±1．23）μg·L－1及（5．98±1．36）、（3．42±1．03）μg·L－1]（均 P ＜0．05）。膀胱癌组术后血清 sFas 和 sFasL 含量与对照组比较差异均无统计学意义（均 P ＞0．05）。浸润性膀胱癌患者血清中 sFas 和 sFasL含量均显著高于浅表性膀胱癌患者（均 P ＜0．05）；膀胱癌 G3期患者血清中 sFas 和 sFasL 含量均显著高于 G1、G2期患者（均 P ＜0．05）。结论血清中 sFas 和 sFasL 水平可能成为膀胱癌患者病理特征判断以及治疗过程中疗效观察的指标。
目的：探討血清可溶性 Fas（sFas）及 FasL（sFasL）含量變化與膀胱癌病理特徵的關繫，以確定血清 sFas 及sFasL 含量檢測在臨床上的應用價值。方法採用酶聯免疫吸附試驗（Elisa）定量檢測78例膀胱癌患者（膀胱癌組，淺錶性膀胱癌54例，浸潤性膀胱癌24例；G1期20例，G2期39例，G3期19例）術前、術後和30例健康體檢者（對照組）血清中 sFas 和 sFasL 的水平。觀察血清 sFas 和 sFasL 含量的變化與膀胱癌病理特徵的關繫。結果膀胱癌組術前血清中 sFas 和 sFasL 含量分彆為（18．53±1．74）、（13．46±1．57）μg·L－1，明顯高于術後及對照組[（7．03±1．54）、（4．38±1．23）μg·L－1及（5．98±1．36）、（3．42±1．03）μg·L－1]（均 P ＜0．05）。膀胱癌組術後血清 sFas 和 sFasL 含量與對照組比較差異均無統計學意義（均 P ＞0．05）。浸潤性膀胱癌患者血清中 sFas 和 sFasL含量均顯著高于淺錶性膀胱癌患者（均 P ＜0．05）；膀胱癌 G3期患者血清中 sFas 和 sFasL 含量均顯著高于 G1、G2期患者（均 P ＜0．05）。結論血清中 sFas 和 sFasL 水平可能成為膀胱癌患者病理特徵判斷以及治療過程中療效觀察的指標。
목적：탐토혈청가용성 Fas（sFas）급 FasL（sFasL）함량변화여방광암병리특정적관계，이학정혈청 sFas 급sFasL 함량검측재림상상적응용개치。방법채용매련면역흡부시험（Elisa）정량검측78례방광암환자（방광암조，천표성방광암54례，침윤성방광암24례；G1기20례，G2기39례，G3기19례）술전、술후화30례건강체검자（대조조）혈청중 sFas 화 sFasL 적수평。관찰혈청 sFas 화 sFasL 함량적변화여방광암병리특정적관계。결과방광암조술전혈청중 sFas 화 sFasL 함량분별위（18．53±1．74）、（13．46±1．57）μg·L－1，명현고우술후급대조조[（7．03±1．54）、（4．38±1．23）μg·L－1급（5．98±1．36）、（3．42±1．03）μg·L－1]（균 P ＜0．05）。방광암조술후혈청 sFas 화 sFasL 함량여대조조비교차이균무통계학의의（균 P ＞0．05）。침윤성방광암환자혈청중 sFas 화 sFasL함량균현저고우천표성방광암환자（균 P ＜0．05）；방광암 G3기환자혈청중 sFas 화 sFasL 함량균현저고우 G1、G2기환자（균 P ＜0．05）。결론혈청중 sFas 화 sFasL 수평가능성위방광암환자병리특정판단이급치료과정중료효관찰적지표。
Objective To explore the relationships of serum soluble Fas (sFas)and soluble FasL (sFasL)levels to pathological characters of bladder cancer,and to identify the clinical value of the detection of serum sFas and sFasL levels.Methods Serum sFas and sFasL levels were de-tected by ELISA in 30 healthy subjects (control group)and 78 patients with bladder cancer (bladder cancer group,54 cases of superficial bladder cancer and 24 cases of invasive bladder canc-er;20 cases of G1 tumors,39 cases of G2 tumors and 19 cases of G3 tumors).The relationships of serum sFas and sFasL levels to pathological characters of bladder cancer were analyzed.Results In patients with bladder cancer,serum sFas and sFasL levels measured before operation were sig-nificantly higher than those measured after operation [(18.53±1.74)and (13.46±1.57)μg· L-1 vs (7.03±1.54)and (4.38±1.23)μg·L-1 ,respectively;P <0.05].Before operation,ser-um sFas and sFasL levels in bladder cancer group were significantly higher than those in control group [(18.53±1.74)and (13.46 ± 1.57)μg·L-1 vs (5.98± 1.36)and (3.42 ± 1.03)μg· L-1 ,respectively;P <0.05].There were no significant differences in serum sFas and sFasL levels between bladder cancer group and control group after operation (P > 0.05).Serum sFas and sFasL levels in patients with invasive bladder cancer were significantly higher than those in pa-tients with superficial bladder cancer (P <0.05).Serum sFas and sFasL levels in patients with G3 tumors were significantly higher than those in patients with G1 or G2 tumors (P <0.05).Conclu-sion Serum sFas and sFasL levels may be used to identify the pathological characters and to as-sess the curative efficacy in patients with bladder cancer.
